SEC Company Response from Lineage Cell Therapeutics, Inc. (LCTX) (CIK 0000876343) (LCTX) — Sep 24, 2013
Lineage Cell Therapeutics, Inc. (LCTX) (CIK 0000876343)
Date: Sept. 24, 2013 · CIK: 0000876343 · Accession: 0001140361-13-036808
AI Filing Summary & Sentiment
Reasoning
Letter
RE:
BIOTIME, INC.
1301 Harbor Bay Parkway, Suite 100
Alameda, California 94502
September 24, 2013
Securities and Exchange Commission
100 F Street, NE
Washington, DC 20549
BioTime, Inc.
Registration Statement on Form S-3
File No. 333- 187710
Ladies/Gentlemen:
The undersigned registrant hereby requests that its Registration Statement on Form S-3, as amended, File No. 333- 187710, be declared effective at 9:30 a.m. on Friday, September 27, 2013, or as soon thereafter as practicable.
The registrant acknowledges that:
· should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve BioTime, Inc. from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
· BioTime, Inc. may not assert this action as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Sincerely,
s/Robert W. Peabody
Show Raw Text
CORRESP 1 filename1.htm BIOTIME, INC. 1301 Harbor Bay Parkway, Suite 100 Alameda, California 94502 September 24, 2013 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 RE: BioTime, Inc. Registration Statement on Form S-3 File No. 333- 187710 Ladies/Gentlemen: The undersigned registrant hereby requests that its Registration Statement on Form S-3, as amended, File No. 333- 187710, be declared effective at 9:30 a.m. on Friday, September 27, 2013, or as soon thereafter as practicable. The registrant acknowledges that: · should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; · the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve BioTime, Inc. from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and · BioTime, Inc. may not assert this action as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Sincerely, s/Robert W. Peabody Senior Vice President Chief Operating Officer and Chief Financial Officer